NYSE:MDT - Medtronic Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
Get Started
$86.30 +0.17 (+0.20 %)
(As of 06/21/2018 04:00 PM ET)
Previous Close$86.13
Today's Range$85.63 - $86.80
52-Week Range$76.41 - $89.72
Volume3.40 million shs
Average Volume5.18 million shs
Market Capitalization$117.39 billion
P/E Ratio18.09
Dividend Yield2.12%
Beta0.94
Medtronic logoMedtronic plc manufactures and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. The company's Cardiac and Vascular Group segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; diagnostics and monitoring devices; mechanical circulatory support, TYRX, and AF products; and remote monitoring and patient-centered software. It also provides transcatheter heart valves, percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, peripheral vascular products, and products to treat superficial and deep venous diseases. Its Minimally Invasive Therapies Group segment offers surgical care, wound closure, electrosurgical, hernia mechanical device, mesh implant, ablation, interventional lung, ventilator, capnography, airway, sensor, monitor, compression, dialysis, enteral feeding, wound care, and medical surgical products; stapling, vessel sealing, fixation, and hardware instruments; and gastrointestinal, temperature management, inhalation therapy, and renal care solutions. The company's Restorative Therapies Group segment offers products for spine, bone graft substitutes, biologic products, trauma, implantable neurostimulation therapies, and drug delivery systems for the treatment of chronic pain, movement disorders, obsessive-compulsive disorder, overactive bladder, urinary retention, fecal incontinence, and gastroparesis, as well as products to treat conditions of the ear, nose, and throat; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems; and therapies for vasculature in and around the brain. The company's Diabetes Group segment offers insulin pumps and consumables, continuous glucose monitoring systems, and Web-based therapy management software. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Receive MDT News and Ratings via Email

Sign-up to receive the latest news and ratings for MDT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:MDT
CUSIP58505510
Webwww.medtronic.com
Phone353-1438-1700

Debt

Debt-to-Equity Ratio0.47
Current Ratio2.28
Quick Ratio1.92

Price-To-Earnings

Trailing P/E Ratio18.09
Forward P/E Ratio16.86
P/E Growth2.37

Sales & Book Value

Annual Sales$29.95 billion
Price / Sales3.91
Cash Flow$6.7369 per share
Price / Cash12.81
Book Value$37.50 per share
Price / Book2.30

Profitability

EPS (Most Recent Fiscal Year)$4.77
Net Income$3.10 billion
Net Margins10.36%
Return on Equity12.84%
Return on Assets6.84%

Miscellaneous

Employees91,000
Outstanding Shares1,355,370,000

Medtronic (NYSE:MDT) Frequently Asked Questions

What is Medtronic's stock symbol?

Medtronic trades on the New York Stock Exchange (NYSE) under the ticker symbol "MDT."

How often does Medtronic pay dividends? What is the dividend yield for Medtronic?

Medtronic announced a quarterly dividend on Friday, March 9th. Stockholders of record on Friday, March 23rd will be given a dividend of $0.46 per share on Friday, April 13th. This represents a $1.84 dividend on an annualized basis and a dividend yield of 2.13%. The ex-dividend date is Thursday, March 22nd. View Medtronic's Dividend History.

How will Medtronic's stock buyback program work?

Medtronic declared that its Board of Directors has approved a share buyback program on Thursday, October 5th 2017, which allows the company to repurchase $5,000,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to buy up to 49% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company's leadership believes its shares are undervalued.

How were Medtronic's earnings last quarter?

Medtronic PLC (NYSE:MDT) posted its quarterly earnings results on Thursday, May, 24th. The medical technology company reported $1.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.39 by $0.03. The medical technology company had revenue of $8.14 billion for the quarter, compared to analyst estimates of $8 billion. Medtronic had a net margin of 10.36% and a return on equity of 12.84%. The company's quarterly revenue was up 2.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.33 earnings per share. View Medtronic's Earnings History.

When is Medtronic's next earnings date?

Medtronic is scheduled to release their next quarterly earnings announcement on Tuesday, August, 21st 2018. View Earnings Estimates for Medtronic.

What guidance has Medtronic issued on next quarter's earnings?

Medtronic updated its FY19 earnings guidance on Thursday, May, 24th. The company provided earnings per share (EPS) guidance of $5.10-5.15 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.14.

What price target have analysts set for MDT?

22 Wall Street analysts have issued 1 year target prices for Medtronic's shares. Their forecasts range from $80.00 to $103.00. On average, they expect Medtronic's stock price to reach $92.8158 in the next year. View Analyst Ratings for Medtronic.

What are Wall Street analysts saying about Medtronic stock?

Here are some recent quotes from research analysts about Medtronic stock:
  • 1. According to Zacks Investment Research, "Medtronic exited the fiscal second quarter on a mixed note. While the company demonstrated improved segmental performances at CER, escalating costs and expenses continue to weigh on the bottom line. Unfavorable currency translation also acted as a dampener. On the bright side, all major business groups contributed to solid top-line growth at CER, which highlighted sustainability across groups and regions, in addition to displaying successful integration and achievement of synergy targets. We are also encouraged by the solid growth trend in the United States as well as healthy global acceptance of its advanced therapies. The recent receipt of FDA approval and commercial launch of Azure pacemakers with BlueSync technology buoy optimism. Apart from product innovation, the company is focusing on geographical diversification of its businesses. The stabilizing trend in the global Cardiac Rhythm & Heart Failure (CRHF) market is another upside." (11/23/2017)
  • 2. Needham & Company LLC analysts commented, "On 11/8/17, MDT preannounced F2Q18 revenue of $7.050B (up 3% organic Y/Y) vs. consensus of $6.897M. The impact from Hurricane Maria was revised down to ~$60M from ~$250M, which equates to ~1% in quarterly revenue growth and ~$0.03 in non-GAAP EPS. MDT did not update its FY18 revenue or EPS guidance in the press release but did reaffirm F2Q18 non-GAAP EPS growth of flat to slightly up, excluding the ~$0.03 headwind. MDT is scheduled to report full F2Q18 results on 11/21/17 and we intend to wait until then to update our model." (11/9/2017)

Who are some of Medtronic's key competitors?

Who are Medtronic's key executives?

Medtronic's management team includes the folowing people:
  • Mr. Omar S. Ishrak, Chairman and Chief Exec. Officer (Age 62)
  • Ms. Karen L. Parkhill, Exec. VP & CFO (Age 53)
  • Mr. Michael J. Coyle, Exec. VP and Group Pres of Cardiac & Vascular Group (Age 56)
  • Mr. Robert J. W. ten Hoedt, Exec. VP and Group Pres, Europe, Middle East & Africa (Age 57)
  • Mr. Mark Ploof, Sr. VP of Global Operations & Bus. Services

Has Medtronic been receiving favorable news coverage?

News coverage about MDT stock has been trending somewhat negative on Thursday, according to Accern Sentiment. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Medtronic earned a news impact score of 0.00 on Accern's scale. They also assigned news stories about the medical technology company an impact score of 45.49 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are Medtronic's major shareholders?

Medtronic's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.08%), Massachusetts Financial Services Co. MA (4.42%), Franklin Resources Inc. (2.65%), Artisan Partners Limited Partnership (1.66%), Northern Trust Corp (1.19%) and Barrow Hanley Mewhinney & Strauss LLC (1.12%). Company insiders that own Medtronic stock include Bradley E Lerman, Bryan C Hanson, Carol A Surface, Gary Lee Ellis, Geoffrey Martha, Hoedt Rob Ten, Hooman Hakami, James T Lenehan, Kendall J Powell, Omar Ishrak, Richard H Anderson, Richard Kuntz, Robert C Pozen and Shirley A Jackson. View Institutional Ownership Trends for Medtronic.

Which institutional investors are selling Medtronic stock?

MDT stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Asset Management One Co. Ltd., Point72 Asset Management L.P., Amundi Pioneer Asset Management Inc., OppenheimerFunds Inc., Swiss National Bank, Massachusetts Financial Services Co. MA and Barrow Hanley Mewhinney & Strauss LLC. Company insiders that have sold Medtronic company stock in the last year include Bradley E Lerman, Bryan C Hanson, Carol A Surface, Hooman Hakami, James T Lenehan, Omar Ishrak and Richard Kuntz. View Insider Buying and Selling for Medtronic.

Which institutional investors are buying Medtronic stock?

MDT stock was bought by a variety of institutional investors in the last quarter, including Rockefeller Capital Management L.P., Westwood Holdings Group Inc., BlackRock Inc., Summit Trail Advisors LLC, Wells Fargo & Company MN, Artisan Partners Limited Partnership, OMERS ADMINISTRATION Corp and Neuberger Berman Group LLC. Company insiders that have bought Medtronic stock in the last two years include James T Lenehan, Richard H Anderson and Robert C Pozen. View Insider Buying and Selling for Medtronic.

How do I buy shares of Medtronic?

Shares of MDT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Medtronic's stock price today?

One share of MDT stock can currently be purchased for approximately $86.30.

How big of a company is Medtronic?

Medtronic has a market capitalization of $117.39 billion and generates $29.95 billion in revenue each year. The medical technology company earns $3.10 billion in net income (profit) each year or $4.77 on an earnings per share basis. Medtronic employs 91,000 workers across the globe.

How can I contact Medtronic?

Medtronic's mailing address is 20 ON HATCH LOWER HATCH STREET, DUBLIN L2, D02. The medical technology company can be reached via phone at 353-1438-1700 or via email at [email protected]


MarketBeat Community Rating for Medtronic (MDT)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  923 (Vote Outperform)
Underperform Votes:  593 (Vote Underperform)
Total Votes:  1,516
MarketBeat's community ratings are surveys of what our community members think about Medtronic and other stocks. Vote "Outperform" if you believe MDT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/21/2018 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.